Author

IT Ocal

Observed name: I Ocal

Institutions: Inova Health System, University of Minnesota, Mayo Clinic, Emory University, Georgetown University, Johns Hopkins Medicine, Moffitt Cancer Center, National Cancer Institute, Berry Consultants, LLC (United States)

Observed institutions: Inova Health System, Translational Genomics Research Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Minnesota, Mayo Clinic, Emory University, Georgetown University, Washington University in St. Louis, Johns Hopkins Medicine, Tianjin Medical University Cancer Institute and Hospital, Moffitt Cancer Center, Clinical Center University of Sarajevo, Mayo Clinic in Arizona, Mayo Clinic Hospital, Caris Life Sciences (United States), National Cancer Institute, Berry Consultants, LLC (United States), Arizona State University, Tianjin Medical University

OpenAlex ID: A5111255379

Abstract P2-07-03: Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden

2019 · NM Hylton, WF Symmans, et al. · Cancer Research

Abstract PD2-11: Contrast-enhanced spectral mammography is comparable to MRI in the assessment of residual breast cancer following neoadjuvant systemic therapy

2018 · T Hilal, M Covington, et al. · Cancer Research

Abstract P6-07-17: A novel fluorescence in situ hybridization assay to detect 9p24.1 amplification in triple negative breast cancer

2017 · M Chen, M Andreozzi, et al. · Cancer Research

Abstract P2-04-18: JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple negative breast cancer

2017 · M Chen, B Pockaj, et al. · Cancer Research

Abstract PD5-03: Effect of PD-1 and PD-L1 in the tumor microenvironment on overall survival of triple-negative breast cancer patients

2017 · ME Linnaus, H Kosiorek, et al. · Cancer Research

Abstract P1-05-19: Homologous recombination deficiency in PD-L1, PD-L2, Jak2 (PDJ) amplified triple negative breast carcinoma

2017 · CD Gawryletz, KS Anderson, et al. · Cancer Research

Abstract P1-03-13: Immunohistochemistry cannot be used to detect PD-L1/JAK-2 amplification

2017 · ME Linnaus, H Kosiorek, et al. · Cancer Research

Abstract P4-09-19: Comprehensive multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast

2016 · Z Gatalica, S Vranic, et al. · Cancer Research

Works count: 8

Citation count:

H-index:

I10-index: